Insulin secretion in rats with chronic nitric oxide synthase blockade

Area of Science:

• Physiology
• Endocrinology
• Pharmacology

Background:

• Nitric oxide (NO), synthesized from L-arginine, is a crucial signaling molecule.
• NO's potential role in insulin secretion via the cyclic guanosine monophosphate (cGMP) pathway is under investigation.

Purpose of the Study:

• To investigate the role of the nitric oxide pathway in insulin secretion.
• To evaluate insulin response to secretagogues after chronic nitric oxide-synthase inhibition.

Main Methods:

• Rats received chronic oral administration of NG-nitro-L-arginine methyl ester (L-NAME) to inhibit nitric oxide-synthase.
• Blood pressure and aortic cGMP levels were monitored as indicators of NO blockade.
• Insulin secretion was measured following intravenous D-glucose, L-arginine, or D-arginine challenges.

Main Results:

• Chronic L-NAME treatment increased blood pressure by 30% and reduced aortic cGMP by seven-fold.
• No significant changes were observed in body weight, fasting glucose, or fasting insulin levels.
• Insulin secretion in response to glucose, L-arginine, and D-arginine remained unaltered in L-NAME treated rats compared to controls.

Conclusions:

• Chronic nitric oxide-synthase blockade effectively inhibits the NO pathway, as evidenced by increased blood pressure and reduced cGMP.
• The nitric oxide pathway does not appear to significantly influence insulin secretion in response to common secretagogues under these conditions.
• Oral L-NAME administration in rats serves as a viable model for studying the L-arginine-nitric oxide pathway.